日本語 
PHC Corporation’s Biomedical Division has launched LiCellGrow, a new cell expansion system aimed at tightening control in cell and gene therapy manufacturing. The system, released for research use in Japan and select global markets, focuses on one stubborn industry problem. Variability.
Cell and gene therapies have progressed rapidly, particularly through their applications in cancer treatment and genetic disorder research. The production process for these therapies presents significant challenges. Cell behavior shifts. Yields fluctuate. Costs climb. Developers struggle to lock in critical process parameters and maintain consistent quality at scale.
LiCellGrow™ tackles this with proprietary in line monitoring that continuously measures glucose and lactate, two core indicators of cell metabolism. Based on real time data, the system automatically adjusts culture conditions. No manual sampling. No guesswork. The goal is tighter process control, better cell quality, and fewer production losses.
Also Read: Total Brain Care Partners with Jonan Shingaku Kenkyusha
Built on PHCbi’s electrochemical sensing platform, the system also uses single use culture bags to support closed, aseptic operations inside standard CO₂ incubators. With planned additions such as filtration bags and cGMP compliant consumables, PHCbi is positioning the platform to support scale up from early research to commercial therapies, including CAR T.
English